SG11201908477QA - Analogs of deutetrabenazine, their preparation and use - Google Patents
Analogs of deutetrabenazine, their preparation and useInfo
- Publication number
- SG11201908477QA SG11201908477QA SG11201908477QA SG11201908477QA SG 11201908477Q A SG11201908477Q A SG 11201908477QA SG 11201908477Q A SG11201908477Q A SG 11201908477QA SG 11201908477Q A SG11201908477Q A SG 11201908477QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- deutetrabenazine
- pct
- analogs
- english
- Prior art date
Links
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 title abstract 4
- 229950005031 deutetrabenazine Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- FWXAUDSWDBGCMN-DNQXCXABSA-N [(2r,3r)-3-diphenylphosphanylbutan-2-yl]-diphenylphosphane Chemical compound C=1C=CC=CC=1P([C@H](C)[C@@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 FWXAUDSWDBGCMN-DNQXCXABSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471484P | 2017-03-15 | 2017-03-15 | |
| PCT/US2018/022562 WO2018170214A1 (en) | 2017-03-15 | 2018-03-15 | Analogs of deutetrabenazine, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908477QA true SG11201908477QA (en) | 2019-10-30 |
Family
ID=61873991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908477Q SG11201908477QA (en) | 2017-03-15 | 2018-03-15 | Analogs of deutetrabenazine, their preparation and use |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11813232B2 (es) |
| EP (1) | EP3596077A1 (es) |
| JP (3) | JP2020510073A (es) |
| KR (2) | KR20200003791A (es) |
| CN (1) | CN110709398A (es) |
| AR (1) | AR111182A1 (es) |
| AU (2) | AU2018236336B2 (es) |
| BR (1) | BR112019018966A2 (es) |
| CA (1) | CA3056612A1 (es) |
| CL (1) | CL2019002629A1 (es) |
| CO (1) | CO2019011271A2 (es) |
| EA (1) | EA201992168A1 (es) |
| IL (1) | IL269132A (es) |
| MX (1) | MX2019010913A (es) |
| PE (1) | PE20191819A1 (es) |
| SG (1) | SG11201908477QA (es) |
| TW (1) | TWI772382B (es) |
| UA (1) | UA127052C2 (es) |
| WO (1) | WO2018170214A1 (es) |
| ZA (1) | ZA201906326B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123393A1 (en) * | 2018-12-13 | 2020-06-18 | Auspex Pharmaceuticals, Inc. | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
| WO2020165807A1 (en) * | 2019-02-14 | 2020-08-20 | Dr. Reddy's Laboratories Limited | Solid forms of deutetrabenazine and process for the preparation thereof |
| US11311488B2 (en) * | 2020-06-10 | 2022-04-26 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2081929T3 (pl) | 2006-11-08 | 2013-06-28 | Neurocrine Biosciences Inc | Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania |
| CN104311552A (zh) | 2008-09-18 | 2015-01-28 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2 的苯并喹啉抑制剂 |
| EP3351247A1 (en) * | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| CA3124804C (en) * | 2012-09-18 | 2023-08-22 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9550780B2 (en) * | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3076970A4 (en) * | 2013-12-03 | 2017-07-26 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| CN114796209A (zh) | 2015-03-06 | 2022-07-29 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
-
2018
- 2018-03-15 PE PE2019001871A patent/PE20191819A1/es unknown
- 2018-03-15 MX MX2019010913A patent/MX2019010913A/es unknown
- 2018-03-15 CA CA3056612A patent/CA3056612A1/en active Pending
- 2018-03-15 KR KR1020197030354A patent/KR20200003791A/ko not_active Application Discontinuation
- 2018-03-15 AR ARP180100611A patent/AR111182A1/es unknown
- 2018-03-15 TW TW107108832A patent/TWI772382B/zh active
- 2018-03-15 WO PCT/US2018/022562 patent/WO2018170214A1/en unknown
- 2018-03-15 EA EA201992168A patent/EA201992168A1/ru unknown
- 2018-03-15 AU AU2018236336A patent/AU2018236336B2/en active Active
- 2018-03-15 BR BR112019018966A patent/BR112019018966A2/pt active Search and Examination
- 2018-03-15 EP EP18715393.7A patent/EP3596077A1/en active Pending
- 2018-03-15 SG SG11201908477Q patent/SG11201908477QA/en unknown
- 2018-03-15 US US15/922,329 patent/US11813232B2/en active Active
- 2018-03-15 CN CN201880018609.8A patent/CN110709398A/zh active Pending
- 2018-03-15 UA UAA201910309A patent/UA127052C2/uk unknown
- 2018-03-15 KR KR1020227043234A patent/KR20230003308A/ko not_active Application Discontinuation
- 2018-03-15 JP JP2019550774A patent/JP2020510073A/ja active Pending
-
2019
- 2019-09-04 IL IL26913219A patent/IL269132A/en unknown
- 2019-09-13 CL CL2019002629A patent/CL2019002629A1/es unknown
- 2019-09-25 ZA ZA2019/06326A patent/ZA201906326B/en unknown
- 2019-09-25 US US16/582,362 patent/US11179386B2/en active Active
- 2019-10-10 CO CONC2019/0011271A patent/CO2019011271A2/es unknown
-
2021
- 2021-10-21 US US17/507,037 patent/US20220040170A1/en active Pending
- 2021-11-30 US US17/537,663 patent/US20220088006A1/en not_active Abandoned
-
2022
- 2022-05-18 AU AU2022203369A patent/AU2022203369B2/en active Active
- 2022-11-04 JP JP2022177578A patent/JP2023010754A/ja active Pending
-
2024
- 2024-01-30 JP JP2024011974A patent/JP2024050724A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018170214A1 (en) | 2018-09-20 |
| CO2019011271A2 (es) | 2020-02-28 |
| IL269132A (en) | 2019-11-28 |
| BR112019018966A2 (pt) | 2020-04-22 |
| UA127052C2 (uk) | 2023-03-29 |
| AU2022203369A1 (en) | 2022-06-09 |
| KR20230003308A (ko) | 2023-01-05 |
| US20220088006A1 (en) | 2022-03-24 |
| EP3596077A1 (en) | 2020-01-22 |
| JP2023010754A (ja) | 2023-01-20 |
| TW201840317A (zh) | 2018-11-16 |
| JP2020510073A (ja) | 2020-04-02 |
| CA3056612A1 (en) | 2018-09-20 |
| AR111182A1 (es) | 2019-06-12 |
| JP2024050724A (ja) | 2024-04-10 |
| PE20191819A1 (es) | 2019-12-27 |
| EA201992168A1 (ru) | 2020-03-16 |
| US11179386B2 (en) | 2021-11-23 |
| US20200016148A1 (en) | 2020-01-16 |
| US11813232B2 (en) | 2023-11-14 |
| AU2018236336A1 (en) | 2019-10-24 |
| TWI772382B (zh) | 2022-08-01 |
| AU2022203369B2 (en) | 2024-04-04 |
| AU2018236336B2 (en) | 2022-02-24 |
| MX2019010913A (es) | 2020-01-20 |
| US20180263972A1 (en) | 2018-09-20 |
| CL2019002629A1 (es) | 2020-01-24 |
| CN110709398A (zh) | 2020-01-17 |
| US20220040170A1 (en) | 2022-02-10 |
| ZA201906326B (en) | 2022-12-21 |
| KR20200003791A (ko) | 2020-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11201908477QA (en) | Analogs of deutetrabenazine, their preparation and use | |
| SG11201407599SA (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| SG11201809494VA (en) | Pharmaceutical composition comprising eteplirsen | |
| SG11201907844TA (en) | Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders | |
| SG11201810358YA (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| SG11201900515PA (en) | Succinate forms and compositions of bruton's tyrosine kinase inhibitors | |
| SG11201809031XA (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| SG11201907153RA (en) | Topical formulations and methods |